0026-895X/93/061094-11$03.00/0

MOLECULAR PHARMACOLOGY, 44:1094-1104

(13)

Structural and Conformational Features Determining Selective Signal Transduction in the β3-Adrenergic Receptor

NATHALIE BLIN, LUC CAMOIN, BERNARD MAIGRET, and A. DONNY STROSBERG

Institut Cochin de Génétique Moléculaire, CNRS-UPR 0415, and Université Paris VII, 75014 Paris, France (N.B., L.C., A.D.S.), and Laboratoire de Chimie Théorique, Université de Nancy I, 54506 Vandoeuvre Les Nancy, France (B.M.)

Received April 23, 1993; Accepted September 11, 1993

SUMMARY

With respect to the β1- and β2-adrenergic receptors (ARs), the β3-AR induces specific physiological effects in a few target tissues and exhibits atypical pharmacological properties that distinguish it unambiguously from its counterparts. Therefore, the β3-AR represents a suitable model to study the molecular mechanism responsible for receptor subtype selectivity and specificity. Potent β3-AR ligands newly characterized in Chinese hamster ovary cells expressing the β3-AR were also evaluated in Chinese hamster ovary cells expressing β1- and β2-ARs and were classified into three groups according to their pharmacological properties. Among the β1/β2/β3 agonists BRL 37344 and LY 79771 exhibit β3 selectivity in stimulating adenylyl cyclase; among the β1/β2 antagonists displaying β3 agonistic effects ICI 201651 exhibits β3-AR binding selectivity, whereas among the β1/β2/β3 antagonist class bupranolol is the most efficient (but not selective) β3-AR antagonist. The structures of these ligands were simulated and compared using computer-generated molecular modeling. Structure-activity relationship analysis indicates that potent or selective β3-AR compounds, in addition to possessing a pharmacophore common to all β-AR ligands, contain a long and bulky alkylamine substituent moiety, which is able to adopt and exchange extended and stacked conformations. Computerized three-dimensional models of the β1-, β2-, and β3-AR binding sites show that more bulky amino acid side chains point inside the groove of the β1 and β2 sites, compared with the β3 site, in a region implicated in signal processing. The long alkylamine chain of compounds behaving as β1/β2 antagonists and β3 agonists may thus adopt either a stacked conformation in the encumbered β1- and β2-AR sites, leading to antagonistic effects, or an extended conformation in the less encumbered β3 site, thus interacting with specific residues implicated in signal transduction.

Sympathetic stimulation via humoral (adrenergic) and neuronal (noradrenergic) pathways induces a number of physiological effects, such as modulation of heart rate, vascular tonus, bronchospasm, and glucose and lipid metabolism. Lands *et al.* (1) first subdivided the β-AR-mediated effects into β1 and β2, on the basis of the rank order of potency of epinephrine and norepinephrine in different tissues. Since this classification, many clinically active drugs, mimicking or blocking the effects of natural hormones, have been synthesized and shown to discriminate between β1- and β2-AR-mediated effects.

In the following years, however, a number of novel compounds revealed atypical β-AR properties in various tissues. BRL 37344 was thus characterized as a potent thermogenic and lipolytic β-AR agonist in rat adipose tissue (2) and SR 58611A as an atypical β-AR agonist mediating relaxation in precontracted guinea pig ileum (3). Several β1/β2 antagonists displayed atypically low binding affinities in these tissues as well as low potencies in inhibiting responses mediated by these novel compounds, thus suggesting the existence of a novel β-AR pharmacological profile. However, partly because of its low

This work was supported by grants from the Centre National de la Recherche Scientifique, the Institut National de la Santé et de la Recherche Médicale, the Ministère de la Recherche et de l'Espace, the Université Paris V, Bristol-Myers-Squibb Company (Princeton, NJ), the Fondation pour la Recherche Médicale, the Association pour le Développement de la Recherche sur le Cancer, and the Ligue Nationale Française contre le Cancer.

ABBREVIATIONS: β-AR, β-adrenergic receptor; CHO, Chinese hamster ovary; CHO-β, Chinese hamster ovary cells expressing the β-adrenergic receptor; IA, intrinsic activity; ICYP, Iodocyanopindolol; MD, molecular dynamics; RMS, root mean square index; TM, transmembrane domain; BRL 37344, (*RR,SS*)-(±)-4-(2′-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl)phenoxyacetate sodium salt sesquihydrate; bucindolol, 2-[2-hydroxy-3-([2-(3-indolyl)-1,1-dimethylethyl]amino)propoxy]benzonitrile hydrochloride; bupranolol, 1-(2-chloro-5-methylphenoxy)-3-[(1,1-dimethylethyl)amino]-2-propanol; CGP 12177A, (±)-4-(3-*t*-butylamino-2-hydroxypropoxy)benzimidazol-2-one; CGP 20712A, (±)-[2-(3-carbamoyl-4-hydroxyphenoxy)ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propanolisopropylamino-2-propanol hydrochloride; cimaterol, 2-amino-5-(1-hydroxy-2-[(1-methylethyl)amino]ethyl)benzonitrile; clenbuterol, 4-amino-3,5-dichloro-α-[(1,1-dimethylethyl)amino]benzenemethanol; ICI 118551, D-(±)-1-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol; ICI 201651, (*R*)-4-(2-hydroxy-3-phenoxypropylaminoethoxy)-*N*-(2-methoxyethyl)phenoxyacetic acid; LY 79771, (*RS*)-(±)-4-(2′-[(2-hydroxy-3-phenylethyl)amino]butyl)benzyl alcohol; SM 11044, L-3-(3,4-dihydroxyphenyl)-*N*-[3-(4-fluorophenyl)propyl]serine pyrrolidine amide hydrobromide; SR 58611A, (*RS*)-*N*-[(2*S*)-7-ethoxycarbonylmethoxy-1,2,3,4-tetrahydronaphth-2-yl]-(2*R*)-2-(3-chlorophenyl)-2-hydroxyethanamine hydrochloride; PBS, phosphate-buffered saline; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid.

affinity for available β-AR radioligands and primarily because of the lack of suitable tools to study its expression among a population of conventional β-ARs, this atypical β-AR remained difficult to characterize unambiguously by a classical pharmacological approach, and some inconsistencies were described between drug affinities identified in binding studies and those measured in functional assays (4).

After the initial cloning of the β2- (5) and β1-ARs (6), a third gene, coding for a novel β-AR subtype (the β3-AR) sharing 51% and 46% identity with the human β1- and β2-AR amino acid sequences, respectively, was cloned from a human genomic library (7). The presence of human β3-AR mRNA transcripts has been demonstrated in human fat tissues as well as in gall bladder and colon biopsies (8), and evidence for a functional β3-AR in human fat cells has been recently shown by lipolysis stimulation studies (9). Functional β3-ARs, cloned from either human (7), mouse (10), or rat (11, 12) tissues, were characterized in transfected CHO cells, and their pharmacological pattern indicated that the β3-AR is closely related to the atypical β-AR in adipose tissues (13, 14). However, minor differences between the human and rodent β3-ARs as well as between atypical β-ARs from different tissues have led some authors to question whether these are actually the same pharmacological subtypes (11, 12, 15).

To settle this point, we performed a systematic pharmacological analysis in CHO-β3 (human) and CHO-β3 (mouse) using a large panel of β-AR ligands, and we showed (i) that both the human and the rodent β3-ARs display well defined pharmacological properties that distinguish them unambiguously from the β1- and β2-ARs, (ii) that the β3-AR is the prototype of the atypical β sites described in a few target tissues (adipose, gut, and cardiac tissues) where it induces specific physiological effects, and (iii) that some compounds (BRL 37344, bucindolol, bupranolol, CGP 12177A, cimaterol, ICI 201651, LY 79771, SR 58611A, and SM 11044) exhibit potent affinities or activities in CHO-β3.[1] These atypical and specific properties make the β3-AR a model receptor to study the molecular basis of subtype selectivity, using these new pharmacological tools.

In this study, we analyzed the selectivity of the subtype by evaluating pharmacological receptor binding and adenylyl cyclase activation properties of β-AR ligands in CHO cells expressing human β1-, β2-, or β3-ARs. Results led us to classify compounds into pharmacological classes, and the structure-activity relationship of these ligands was analyzed using MD simulations. Structural features of β3-efficient agonists and antagonists were examined to define a putative pharmacophore, as well as to provide new insights into the molecular mechanism responsible for the β3-AR potency and selectivity.

Materials and Methods

Chemicals. Bucindolol and nadolol were provided by Bristol-Myers Squibb (Princeton, NJ). CGP 12177A, CGP 20712A, alprenolol, and oxprenolol were gifts from Ciba-Geigy Corporation (Basel, Switzerland). ICI 118551 and ICI 201651 were obtained from Imperial Chemical Industries (Macclesfield, England). Cimaterol and LY 79771 were donated by American Cyanamid (Pearl River, NY) and Lilly Research Labs (Indianapolis, IN), respectively. Clenbuterol was obtained from Roussel Uclaf (Romainville, France). Pindolol and cyanopindolol were provided by Sandoz (Basel, Switzerland). (±)- and (−)-Bupranolol were gifts from Schwarz Pharma (Monheim, Germany). BRL 37344 was obtained from SmithKline Beecham Pharmaceuticals (Epsom, England). SM 11044 and SR 58611A were given by Sumitomo Pharmaceuticals (Osaka, Japan) and Sanofi-Midy (Milano, Italy), respectively. (−)-Isoproterenol and propranolol were purchased from Sigma Chemical Co. (St. Louis, MO).

Cell culture. Subclones of CHO cells stably transfected with human β1-, β2-, or β3-ARs were grown as described previously (7, 16).

Receptor binding assays. Preconfluent cells were harvested by treatment with Versen-EDTA (Seromed) and were washed with Hanks' balanced salt solution supplemented with 1 mM ascorbic acid and buffered with 20 mM HEPES to achieve a pH of 7.4. Aliquots of 10^5 cells were incubated with (−)-[3-^{125}I]ICYP (2000 Ci/mmol; Amersham, England) in the absence or presence of competitor, in a buffered 500-μl final volume with 0.1% (w/v) bovine serum albumin (Sigma) and 4 μM desipramine (Sigma). The reaction was performed for 45 min at 37°, with shaking, in the dark. After dilution with ice-cold PBS, pH 7.4, cells were immediately filtered and extensively washed over glass fiber disks (Whatman GF/C) that had been presoaked with 0.3% polyethyleneimine (Sigma). Radioactivity was measured in a LKB 1282 γ-radiation counter.

Saturation experiments were performed with ICYP concentrations ranging from 5 to 500 pM for the β1- and β2-ARs and from 50 to 5000 pM for the β3-AR. Nonspecific binding was determined in the presence of 2 μM (±)-propranolol for CHO-β1 and CHO-β2 or 100 μM (−)-isoproterenol for CHO-β3. Competition experiments were performed with ICYP concentrations of 50 pM for the β1 and β2 subtypes and 1 nM for the β3 subtype and various concentrations of competitor ranging from 1 pM to 100 μM. Ligand lipophilicity indexes (log ƒF) were calculated using the TSAR software (Oxford Molecular, Oxford, England).

Adenylyl cyclase binding assays. Because forskolin directly stimulates the catalytic subunit of adenylyl cyclase and displays greater efficacy and potency when its catalytic domain interacts with the α_s subunit of the G protein (17), forskolin binding experiments were performed with adherent transfected CHO-β in the absence or presence of β-AR ligands.

Preconfluent cells in six-well dishes (≈1.2 × 10^6 cells/well) were washed twice with 2 ml of ice-cold PBS, added to 1 ml of ice-cold Ham's F12 medium buffered with 20 mM HEPES, pH 7.4, and kept on ice for 30 min before the binding study. Cells were incubated at 4° for 1 hr, with slow shaking, in 500 μl of buffered [12-^{3}H]forskolin (20–35 Ci/mmol; New England Nuclear), in the absence or presence of non-tritiated forskolin or β-AR ligands. Cells were then washed three times with 2 ml of PBS and dissolved in 1 ml of 1 N NaOH for 30 min at 37° before the homogenate was counted in a LKB-Wallac 1410 scintillation counter.

Cholera toxin ADP-ribosylates G_s, irreversibly blocking its GTPase activity and maintaining the stability of the α_s-cyclase complex in a way that is independent of receptor occupancy. Cells were treated with cholera toxin (2 μg/ml in culture medium; Sigma) for 5 hr at 37° before measurement of forskolin binding at 4°, a temperature that allows stabilization of the transient complex but probably leads to underestimation of the maximal complex association at 37°.

Adenylyl cyclase stimulation assays. CHO-β1, CHO-β2, and CHO-β3 were grown to preconfluence in six-well dishes (≈1.2 × 10^6 cells/well). After washing with 1 ml of Ham's F12 medium buffered with 20 mM HEPES, pH 7.4, and supplemented with 1 mM ascorbic acid and 1 mM 3-isobutylmethylxanthine (Sigma), cell monolayers were incubated for 30 min at 37° in 1 ml of buffer, in the absence (basal level, 5–25 pmol/10^6 cells) or in the presence of 10 μM (−)-isoproterenol (maximal stimulation mediated by β-AR, 170–400 pmol/10^6 cells), 25 μM forskolin (direct adenylyl cyclase stimulation, 420–850 pmol/10^6 cells), or 1 pM to 100 μM ligand. The reaction was stopped by one wash with 1 ml of PBS and immediate addition of 500 μl of 1 N NaOH. After a period of 20 min at 37°, dissolved cells were collected, buffered with

[1] N. Blin, C. Nahmias, M. F. Drumare, and A. D. Strosberg. The β3-adrenergic receptor: a single subtype responsible for atypical β-adrenergic receptor-mediated effects. Submitted for publication.

1 N acetic acid, and centrifuged at 3000 × g for 10 min at 4°. The total cAMP amount contained in an aliquot of supernatant was determined using the Amersham [^{3}H]cAMP assay or [^{125}I]-cAMP scintillation proximity assay.

For inhibition studies of adenylyl cyclase stimulation, cells were preincubated with the antagonist at 37° for 10 min before addition of a reference agonist [i.e., (−)-isoproterenol] at its K_{act} concentration (5 nM) and incubation for a subsequent 20-min period.

Data analyses. The data were expressed as the means ± standard errors of at least three independent experiments performed in duplicate, except for forskolin binding data, which resulted from two experiments only. Saturation experiments were computer analyzed with the EBDA program (Biosoft-Elsevier, Cambridge, UK) using the Scatchard plot representation. IC_{50} and EC_{50} parameters obtained from binding competition experiments or adenylyl cyclase activation or inhibition experiments were determined using a computerized, iterative, nonlinear, least squares curve-fitting program (Inplot 4.0, written by H. J. Motulsky, GraphPad Software, San Diego, CA). IC_{50} values measured in binding competition or cyclase antagonism experiments were corrected (K_i value) according to the method of Cheng and Prusoff. The IA of a compound was measured relative to the maximal cyclase stimulation obtained for (−)-isoproterenol. Ligands that possessed IA values of <0.90 were defined as partial agonists.

Molecular modeling. The conformations of the arylethanolamine-related compounds that were incorporated into the analysis were obtained using the BIOSYM molecular modeling software (BIOSYM Technologies, Inc., San Diego, CA) on a Silicon Graphics workstation.

Initial structures were built using the Insight II Builder module, which directly produced coarse three-dimensional starting structures. To mimic ionization at neutral pH, an *sp*3+ hybridization was assigned to the amine of the main alkyl chain, increasing the molecular electrostatic total charge by +1.

Energy minimization and MD simulations were performed with the Insight II Discover module, using the consistent valence force field. All calculations were performed for *in vacuo* conditions, using in the description of the coulombic interaction a distance-dependent dielectric constant fixed to 3.5 to avoid formation of intramolecular salt bridges.

The first step of modeling consisted of minimizing the structure previously conatructed, to find a local energy minimum on the potential energy hypersurface of the molecule. Calculations were performed according to several algorithms commonly used in molecular mechanics minimization for choosing descent directions, namely steepest descent, conjugate gradient, and Newton-Raphson methods.

The second step of the conformational sampling procedure consisted of recording MD trajectories. By solving the equations of motion for a system of atoms, MD has an advantage in that it is not restricted to harmonic motion about a single minima but allows molecules to cross energy barriers and explore other stable conformations. Molecular conformers were sampled during a 1-nsec MD trajectory at 300°K. A time step of 5 fsec was used, and the system was equilibrated for 1 psec. A conformation was stored each 5 psec, so that 200 conformations were recorded by the end of the MD simulation.

All molecular conformations were compared using the Analysis module of Insight II. Conformational similarities were evaluated by calculating the RMS of deviation between heavy atoms for each possible pair of these 200 structures and by plotting the associated cluster graph. A threshold value of 4 Å was selected to plot the RMS evolution, so that numerous boxlike areas appeared along the diagonal, representing group of structures whose small RMS deviations (<1 Å) and closeness in time suggested that they may belong to the same conformational family. Conformational representatives extracted from each family were compared for each compound, as well as between different ligands, using a superimposition procedure.

Results and Discussion

Selectivity of β-AR Ligands in CHO-β1, CHO-β2, and CHO-β3

Although β-AR overexpression has been reported to affect adenylyl cyclase sensitivity (18–20), it offers the opportunity to thoroughly characterize receptors such as the β3-AR, for which high affinity radiolabeled antagonists have not been developed thus far. The human β1-, β2-, and β3-ARs overexpressed in CHO cells displayed selectivity profiles for catecholamines and reference β-AR ligands that were consistent with those described in tissues characterized by prevailing β1-, β2-, and β3-AR populations (16). The presence of six additional carboxyl-terminal residues in the sequence of the human β3-AR, resulting from splicing of an intron in the corresponding gene, has been reported (21, 22), but a recent pharmacological comparison failed to detect any difference between the 408- and 602-residue forms of this receptor (23).

Because the apparent affinity of agonists at ICYP binding sites may be influenced by varying degrees of internalization, we verified that the lipophilicity indices (log *P*) of the β1- and β2-AR agonists tested in CHO-β were higher than that of the ICYP radioligand. For the β3-AR, no bias in measurement of K_i values is expected, because this receptor subtype does not become sequestered (23).

Because differences in the level of receptor expressed in each CHO-β subclone [190,271 ± 16,796 sites/cell in CHO-β1 (human), 74,885 ± 22,461 sites/cell in CHO-β2 (human), and 108,785 ± 5,988 sites/cell in CHO-β3 (human)] and differences in receptor subtype coupling might interfere with the measurement of cyclase stimulation potency, the stoichiometry of receptor-G_s-adenylyl cyclase interactions was assessed in CHO-β1, CHO-β2, and CHO-β3. Because isoproterenol-stimulated forskolin binding measurements revealed approximately the same number of forskolin binding sites in the three types of cells as well as after cholera toxin stimulation (Fig. 1), it appeared that all of the cholera toxin-sensitive G protein coupled-adenylyl cyclase existing in CHO-β was stimulated by isoproterenol. Moreover, it appeared that coupling efficiency of the three β-AR subtypes should not bias the adenylyl cyclase stimulation potency measurements, thus allowing comparison of the β selectivity of ligands based on K_{act} values.

The selectivity of β-AR ligands exhibiting interesting pharmacological properties at the β3 site[1] was evaluated in CHO-β1, CHO-β2, and CHO-β3 and led to the classification of the compounds into three groups, i.e., agonists at the three β sites,



Fig. 1. Measurement of the rate of coupling in CHO-β1, CHO-β2, and CHO-β3. Forskolin binding was evaluated in intact CHO-β1, CHO-β2, and CHO-β3 preincubated (■) or not (□) with 2 μg/ml cholera toxin for 5 hr at 37° and incubated with 100 μM isoproterenol for 1 hr at 4°. Values are the mean ± standard error of two separate experiments performed in duplicate.

β1/β2 antagonists displaying β3 agonistic properties, and antagonists for the β1-, β2-, and β3-ARs (Table 1).

β1/β2/β3 agonists. The β3-AR was characterized by its potency for a class of arylethanolamine agonists that were initially found to be potent and selective activators of lipolysis and thermogenesis at the atypical β-ARs described in white and brown adipose tissues (Table 1). BRL 37344, the most representative compound of this class (2, 24), was a full agonist in CHO-β1 and CHO-β3, with partial agonistic effects (IA = 0.8) in CHO-β2, and exhibited a 10-fold β3-AR selectivity, relative to the β1- and β2-ARs. LY 79771, an activator of the metabolic rate in dogs (25), stimulated adenylyl cyclase with 5- and 17-fold greater potency in CHO-β3 than in CHO-β1 and CHO-β2, respectively. Thus, atypical β-AR compounds, which are potent in inducing thermogenesis in brown adipose tissue and in increasing the rates of cellular metabolism such as lipolysis in white adipose tissue, appeared to be β3-selective ligands.

SR 58611A and SM 11044, which were relaxant agents in the precontracted rat colon (3) and guinea pig ileum (26), respectively, were "rather β2/β3-selective" agonists in CHO-β. SR 58611A, the potent and most selective compound of the phenylethanolaminotetraline class, induced rat colon relaxation with an EC_{50} of 3.5 nM (3), compared with a K_{act} of 25 nM in stimulating CHO-β3 adenylyl cyclase. The SM 11044 functional selectivity order in guinea pig tissues, i.e., ileum relaxation (atypical β-AR) > trachea or lung relaxation (β2-AR) > atrium rate increase (β1-AR), was consistent with the selectivity of this drug in CHO-β1, CHO-β2, and CHO-β3. Although possessing rather low affinities at the β3 site (K_i range of 1–6 μM), these compounds were efficient enough (K_{act} values between 10 and 100 nM) to induce β3-AR-mediated functional relaxation in smooth muscle tissues.

Cimaterol and clenbuterol, reported to induce protein accretion and to increase skeletal muscle mass *in vivo* (25), were "rather β1/β2-selective" agonists in CHO-β. In addition, cimaterol exhibited high efficiency in stimulating the cyclase in CHO-β3, in agreement with its ability to potently activate lipolysis in rat white adipose tissue (25).

β1/β2 antagonists/β3 agonists. Among the β1/β2 antagonists displaying β3 agonistic properties, some exhibited high binding affinities and agonistic potencies in CHO-β3 (Table 1). Bucindolol, described as a high affinity nonselective β-AR antagonist (27), displayed the same binding affinities for β1- and β2-ARs expressed in CHO cells (K_i values of 0.2 nM and 0.1 nM, respectively) and possessed full and potent (K_{act} = 7 nM) β3 agonistic effects. ICI 201651, the *in vivo* metabolized form of ICI D7114 that is able to selectively stimulate brown adipose tissue activity (28), was a weak antagonist at the β1- and β2-AR sites (K_i values of 0.55 μM and 2.86 μM, respectively) but a potent full agonist in CHO-β3 (K_{act} = 20 nM). ICI 201651 was the most important compound of this class, exhibiting a β3 selectivity in binding affinities.

CGP 12177A, oxprenolol, pindolol, and alprenolol were 10–100-fold less potent in stimulating the β3-AR than were the previously mentioned full agonists and, except for alprenolol, demonstrated partial agonistic effects. Pindolol maintained its cyclase stimulation potency when a cyano group was added to the indol function of the molecule (K_{act} value of 153 nM, compared with 174 nM) but displayed an IA that increased from 0.55 to 0.82. These compounds bound to the β1- and β2-ARs with 10–100-fold higher affinities than those measured in CHO-β3.

Nadolol and propranolol were β1/β2 antagonists exhibiting weak (K_{act} values in the micromolar range) and partial agonistic effects in CHO-β3. In agreement with these results, Bond and Clarke (29) reported a biphasic effect for nadolol and propranolol in antagonizing the isoproterenol-induced relaxation of precontracted guinea pig ileum strips.

β1/β2/β3 antagonists. The third category of ligands included antagonists such as the β1-selective CGP 20712A, the β2-selective ICI 118551, and bupranolol (Table 1).

Kaumann (30) earlier reported that heart atypical β agonistic effects were antagonized by 1 μM bupranolol but not propranolol. Although (−)-bupranolol appeared to be the best antagonist available to characterize the β3-AR (K_i value of 50 nM), its receptor binding order of selectivity in CHO-β was β2-AR > β1-AR > β3-AR.

The selectivity profiles for these antagonists were CGP 20712A = bupranolol > ICI 118551 in CHO-β1, bupranolol ≥ ICI 118551 > CGP 20712A in CHO-β2, and bupranolol > ICI 118551 > CGP 20712A in CHO-β3.

Taken together, our data show that β3-selective agonists (BRL 37344 and LY 79771), β3-selective (ICI 201651) and β3-potent (bucindolol and CGP 12177A) agonists that exhibit β1/β2 antagonistic properties, a β3-potent antagonist (bupranolol), and β1- and β2-selective antagonists (CGP 20712A and ICI 118551, respectively) are useful tools that can help to distinguish β3-AR-mediated physiological effects from those mediated by conventional β1- and β2-ARs. To date, only [^{125}I]ICYP and [^{3}H]CGP 12177A have allowed direct characterization of tissue β3-ARs (13). In addition, radiolabeling of ICI 201651, which exhibited binding selectivity towards the β3 site, should provide a new pharmacological tool for the characterization of the β3-AR in tissues. More selective compounds for the β3-AR, however, remain to be found, and analysis of the structure-activity relationships for this large variety of compounds should help in determining the structural features responsible for the β3 potency and selectivity of ligands.

Structural Features of β3-AR Ligands

Fine specificity of the ligand recognition mechanism for G protein-coupled receptors. Norepinephrine stimulated adenylyl cyclase in CHO-β3 with a 1600-fold higher potency, relative to dopamine, which is its metabolic precursor and is specific for dopaminergic receptors (7). Although these compounds are structurally related, β-hydroxylation of the alkylamine chain appears to be important for ligand-receptor recognition. Indeed, this modification creates an asymmetrical center, leading to isomerization of the molecule, and this polar β-hydroxyl group may interact with an electrophilic center and form a hydrogen bond with an amino acid side chain inside the receptor groove.

Similarly, α- and β-ARs were distinguished upon the basis of the potency order of isoproterenol, relative to norepinephrine and epinephrine, three catecholaminergic structures that are closely related. Indeed, isoproterenol differs from (nor)-epinephrine by a (di)methyl substitution, which increases steric bulk and lipophilicity at the end of the alkylamine chain, and the substitution of a methyl group on the protonated amine moiety of norepinephrine corresponds, in thermodynamic calculations, to a loss of 6–7 kcal (31). These modifications seem

TABLE 1

Comparison of the pharmacological properties of human β1-, β2-, and β3-AR expressed in CHO cells

Binding competition assays were carried out with intact cells for 45 min at 37° in the presence of [^{125}I]ICYP, as described in Materials and Methods. Adenylyl cyclase stimula preincubated or not with 5 nM isoproterenol for 10 min and incubated with drugs for 30 min at 37°. Concentration-response curves were fitted using least squares regressio adenylyl cyclase stimulation (K_{act}) constants were deduced. IA was calculated for each drug relative to isoproterenol-induced maximal cAMP accumulation. Values are means ± experiments performed in duplicate. Ligands were classified as β1/β2/β3 agonists (more β3-selective, more β2/β3-selective, or more β1/β2-selective agonists), β1/β2 antagoni data were obtained using similar experimental conditions.

	Human β1-AR			Human β2-AR			
	Binding K_i	Adenylyl cyclase stimulation		Binding K_i	Adenylyl cyclase stimulation		Binding K_i
		K_{act}	IA		K_{act}	IA	
	nM	nM		nM	nM		nM
β1/β2/β3 agonists							
BRL 37344	1,750 ± 310	112 ± 28	1.30 ± 0.11	1,120 ± 380	177 ± 47	0.80 ± 0.04	287 ± 92
LY 79771		86 ± 8	1.42 ± 0.30		325 ± 121	0.22 ± 0.03	555 ± 71
SR 58611A	38,500 ± 13,400	12,000 ± 600	0.96 ± 0.07	187 ± 26	36 ± 19	0.87 ± 0.07	6,640 ± 960
SM 11044	18,100 ± 1,700	190 ± 20	1.50 ± 0.21	4,100 ± 200	62 ± 6	1.03 ± 0.08	1,300 ± 200
Cimaterol		0.64 ± 0.15	1.20 ± 0.06		0.57 ± 0.002	0.98 ± 0.03	4,700 ± 1,71
Clenbuterol	190 ± 30			60 ± 9	1.0 ± 0.2	0.91 ± 0.02	1,100 ± 200
β1/β2 antagonists/β3 agonists							
Bucindolol	0.20 ± 0.04	Antagonist		0.10 ± 0.03	Antagonist		23 ± 10
ICI 201651	549 ± 200	Antagonist		2,860 ± 750	Antagonist		85 ± 12
CGP 12177A	0.9 ± 0.1	Antagonist		4 ± 2	Antagonist		88 ± 22
Oxprenolol	5.4 ± 1.3	Antagonist		1.5 ± 0.4	Antagonist		70 ± 10[b]
Pindolol	3.4 ± 0.7	Antagonist		2.3 ± 0.9	Antagonist		11 ± 2[b]
Cyanopindolol		Angatonist			Antagonist		
Alprenolol	8.8 ± 0.2	Antagonist		1.5 ± 0.3	Antagonist		110 ± 30
Nadolol	40 ± 6	Antagonist		14 ± 5	Antagonist		636 ± 72
Propranolol	6.3 ± 1.0	Antagonist		0.7 ± 0.3	Antagonist		145 ± 8
β1/β2/β3 antagonists							
(−)-Bupranolol	1.7 ± 0.3	Antagonist		0.4 ± 0.1	Antagonist		50 ± 14
(±)-Bupranolol	2.4 ± 0.5	Antagonist		0.5 ± 0.1	Antagonist		106 ± 8
ICI 118551	120 ± 3[c]	Antagonist		1.2 ± 0.2[c]	Antagonist		257 ± 34[b]
CGP 20712A	1.5 ± 0.2[c]	Antagonist		1,800 ± 400[c]	Antagonist		2,300 ± 450[b]

[a] Results reported by Nahmias *et al.* (10), with IA expressed relative to isoproterenol.
[b] Data reported by Emorine *et al.* (7), with IA expressed relative to norepinephrine maximal cyclase stimulation.
[c] Data reported by Tate *et al.* (16).

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.